Dual purpose: some cancer therapies used to treat autoimmune diseases.
Ben-Ari
Elia T
ET
D000911:Antibodies, Monoclonal / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000494:pharmacology; D000077561:Daclizumab; D005060:Europe; D049673:History, 20th Century; D006801:Humans; D007074:Immunoglobulin G / Q000494:pharmacology; D007166:Immunosuppressive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D008466:Mechlorethamine / Q000494:pharmacology; D008727:Methotrexate / Q000494:pharmacology; D009369:Neoplasms / Q000188:drug therapy*; D000069283:Rituximab; D014857:Warfare
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000069283:Rituximab; D008466:Mechlorethamine; D003520:Cyclophosphamide; D000077561:Daclizumab; D008727:Methotrexate